9344 studies found for:    "Growth Substances"
Show Display Options
Download search resultsDownload the search results for:
"Growth Substances" (9344 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Completed A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
Conditions: Metastatic Hepatocellular Carcinoma;   Advanced Liver Cancer
Interventions: Drug: Ascorbic Acid + Sorafenib;   Drug: Sorafenib alone
2 Completed Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca
Condition: Stage IV Pancreatic Cancer
Intervention: Drug: Ascorbic Acid
3 Terminated Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
Condition: Stage IV Colorectal Cancer
Intervention: Drug: Vitamin C
4 Terminated Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
Conditions: Neuroendocrine Tumors;   Pancreatic Neoplasms;   Advanced Disease;   Sunitinib
Intervention: Drug: Sutent
5 Terminated Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma
Conditions: Hepatocellular Carcinoma;   Fibrolamellar Hepatocellular Carcinoma
Intervention: Drug: Sutent
6 Completed Trial of Vitamin D Supplementation for the Prevention of Influenza and Other Respiratory Infections (ViDiFlu)
Conditions: Respiratory Tract Infections;   Influenza
Interventions: Dietary Supplement: Cholecalciferol (Vitamin D/Vigantol oil);   Dietary Supplement: Miglyol oil
7 Terminated Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Conditions: Hepatocellular Carcinoma Non-resectable;   Hepatocellular Carcinoma Recurrent;   Carcinoma, Hepatocellular;   Liver Diseases;   Neoplasms by Histologic Type;   Digestive System Neoplasms;   Carcinoma;   Liver Neoplasms;   Neoplasms;   Neoplasms by Site;   Digestive System Diseases;   Adenocarcinoma;   Neoplasms, Glandular and Epithelial
Interventions: Drug: ABT-869;   Drug: Sorafenib
8 Completed Patellar Tendon Regeneration With Platelet-rich Plasma
Condition: Knee Instability
Interventions: Procedure: Platelet-rich plasma;   Procedure: Control group
9 Terminated Growth Hormone and Heart Failure
Condition: Heart Failure, Congestive
Intervention:
10 Completed A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy
Conditions: HIV Infections;   Peripheral Nervous System Disease
Intervention: Drug: Nerve Growth Factor, Recombinant Human
11 Not yet recruiting Correlation of Functional and Structural Outcomes With Serum Antibody Profiles in Patients With Neovascular Age-related Macular Degeneration Treated With Ranibizumab and Healthy Subjects
Condition: Ranibizumab
Intervention: Drug: Ranibizumab
12 Not yet recruiting Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI
Condition: Glioblastoma
Interventions: Radiation: Avastin;   Radiation: Lomustine;   Radiation: Temozolomide;   Device: MRI;   Device: MRS;   Device: DSC
13 Not yet recruiting Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: elotuzumab;   Drug: Lenalidomide;   Drug: Dexamethasone;   Procedure: autologous stem cell transplantation
14 Active, not recruiting RANDOMISED PHASE II STUDY ASSESSING THE EFFICACY AND SAFETY OF 2 THERAPEUTIC STRATEGIES COMBINING BEVACIZUMAB WITH CHEMOTHERAPY: DE-ESCALATION VERSUS ESCALATION IN PATIENTS WITH NON-PRETREATED UNRESECTABLE METASTATIC COLORECTAL CANCER
Condition: Colorectal Neoplasms
Interventions: Drug: 5 FLUOROURACYL;   Drug: acide folinique;   Drug: irinotecan;   Drug: Oxaliplatin;   Drug: capécitabine;   Drug: bevacizumab
15 Not yet recruiting Hydroxytyrosol and Vitamin E in Pediatric NASH
Condition: NAFLD
Interventions: Drug: Hydroxytyrosol plus Vitamin E;   Drug: Placebo
16 Recruiting Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer
Conditions: Metastatic Colorectal Cancer;   Quality of Life
Intervention: Drug: Bevacizumab
17 Recruiting Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma
Condition: Glioblastoma
Interventions: Drug: F-MISO;   Other: Cerebral magnetic resonance imagery;   Drug: Bevacizumab;   Other: Clinical examination
18 Not yet recruiting Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)
Condition: Low Grade Glioma
Interventions: Drug: Vinblastine;   Drug: Bevacizumab
19 Not yet recruiting Folinic Acid and Language Impairment in Autism Spectrum Disorder
Condition: Autism Spectrum Disorder
Interventions: Drug: Folinic Acid;   Other: Placebo
20 Not yet recruiting Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Atezolizumab;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Quality-of-Life Assessment

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years